FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 256 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib February 10, 2022 Cancer Rehabilitation Starts at Diagnosis July 6, 2021 FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... March 27, 2025 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer August 9, 2022 Load more HOT NEWS When Breast Cancer Patient Comes Into His Shop, Barber Shaves His... Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with... EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan
